Garden State Investment Advisory Services LLC Buys Shares of 16,936 Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Garden State Investment Advisory Services LLC bought a new position in Sarepta Therapeutics, Inc. (NASDAQ:SRPT - Free Report) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 16,936 shares of the biotechnology company's stock, valued at approximately $2,115,000.

A number of other hedge funds also recently made changes to their positions in the company. Innealta Capital LLC purchased a new position in shares of Sarepta Therapeutics in the 2nd quarter valued at $31,000. Nkcfo LLC purchased a new stake in shares of Sarepta Therapeutics during the second quarter worth $43,000. Sunbelt Securities Inc. raised its position in shares of Sarepta Therapeutics by 446.2% during the 3rd quarter. Sunbelt Securities Inc. now owns 284 shares of the biotechnology company's stock valued at $35,000 after buying an additional 232 shares during the period. Huntington National Bank lifted its holdings in Sarepta Therapeutics by 150.9% during the 3rd quarter. Huntington National Bank now owns 291 shares of the biotechnology company's stock worth $36,000 after buying an additional 175 shares in the last quarter. Finally, Riggs Asset Managment Co. Inc. increased its position in shares of Sarepta Therapeutics by 33.3% in the 2nd quarter. Riggs Asset Managment Co. Inc. now owns 300 shares of the biotechnology company's stock valued at $47,000 after purchasing an additional 75 shares during the last quarter. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

Insider Activity

In other Sarepta Therapeutics news, Director Kathryn Jean Boor sold 1,636 shares of the business's stock in a transaction that occurred on Thursday, December 5th. The stock was sold at an average price of $125.55, for a total value of $205,399.80. Following the completion of the sale, the director now owns 5,880 shares in the company, valued at approximately $738,234. The trade was a 21.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 7.70% of the stock is owned by company insiders.

Sarepta Therapeutics Trading Down 0.6 %

SRPT stock traded down $0.76 during trading on Friday, hitting $123.71. The company had a trading volume of 730,761 shares, compared to its average volume of 1,223,790. The stock has a market cap of $11.82 billion, a PE ratio of 98.97 and a beta of 0.77. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93. The business has a 50-day moving average of $123.12 and a 200-day moving average of $131.30. Sarepta Therapeutics, Inc. has a one year low of $89.92 and a one year high of $173.25.

Wall Street Analyst Weigh In

Several research firms have commented on SRPT. Guggenheim upped their price objective on Sarepta Therapeutics from $148.00 to $150.00 and gave the company a "buy" rating in a research note on Thursday, November 7th. HC Wainwright cut their target price on shares of Sarepta Therapeutics from $80.00 to $75.00 and set a "sell" rating for the company in a research report on Tuesday, December 3rd. Robert W. Baird dropped their price objective on Sarepta Therapeutics from $200.00 to $193.00 and set an "outperform" rating for the company in a research report on Thursday, November 7th. Jefferies Financial Group assumed coverage on Sarepta Therapeutics in a report on Monday, October 21st. They issued a "buy" rating and a $165.00 price target for the company. Finally, UBS Group boosted their price objective on shares of Sarepta Therapeutics from $173.00 to $188.00 and gave the company a "buy" rating in a research note on Tuesday, September 17th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Moderate Buy" and an average price target of $178.71.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.